Objective To establish the quality standard for Pudilan Xiaoyan Capsule(PXC).Methods The content of baicalin in PXC was determined by HPLC.The AichromBond-ODS-C18 column(4.6 mm? 150 mm,5 ? m) was used with column temperature being at 30 ℃ and injection volume being 10 ? L.The mobile phase was consisted of CH3OH-H20-H3PO4(40 :60 :0.2) with the flow rate being 1.0 mL/min.The detection wavelength was at 280 nm.Results A good linearity was obtained in the range of 0.062～ 0.372 ? g of baicalin with a good correlation coefficient(r=0.9998).Conclusion The method is accurate and good reproducibility.It can be used effectively for the quality control of Pudilan Xiaoyan Capsule.

Inflammatory bowel disease (IBD) is a complex condition resulting from environmental, microbial, immunologic, and genetic factors. With the advancement of Mendelian randomization research in IBD, we have gained new insights into the relationship between these factors and IBD. Many animal models of IBD have been developed using different methods, but few studies have attempted to model IBD by combining environmental factors and microbial factors. In this review, we examine how environmental factors and microbial factors affect the development and progression of IBD, and how they interact with each other and with the intestinal microbiota. We also summarize the current methods for creating animal models of IBD and compare their advantages and disadvantages. Based on the latest findings from Mendelian randomization studies on the role of environmental factors in IBD, we discuss which environmental and microbial factors could be used to construct a more realistic and reliable IBD experimental model. We propose that animal models of IBD should consider both environmental and microbial factors to better mimic human IBD pathogenesis and to reveal the underlying mechanisms of IBD at the immune and genetic levels.We highlight the importance of environmental and microbial factors in IBD pathogenesis and offer new perspectives and suggestions for improving experimental animal modeling. Our goal is to create a model that closely resembles the clinical picture of IBD.

Objective Nutrition plays an indispensable role in disease prevention,recovery,and medical improvement.The ability of medical staff to master correct nutrition knowledge plays an important role in nutritional support and education for disease recovery.This survey aims to invest the nutritional knowledge,attitudes,and dietary behaviors of medical staff in a tertia-ry hospital in Guangzhou.Methods Questionnaire surveys is conducted as a sampling survey for nutritional knowledge and be-havior in medical staff,including the mastery of nutrition knowledge,nutritional behavior habits,and others.Results Accuracy Rate of nutrition knowledge was only 49.72％in medical staff while 68％present with high enthusiasm for learning nutrition knowledge.Forty-four percent believe that the current public opinion lacks sufficient promotion of nutrition,resulting in a lack of nutrition knowledge and attention to the actual dietary situation.Conclusion Improvement of nutrition knowledge training,dieta-ry structure and lifestyle of medical staff,could promote both their physical health and their patients'health status.

Objective:To evaluate the effect of imatinib on growth impairment in children with chronic myeloid leukemia (CML-CP) in the chronic phase.Methods:From July 2018 to July 2019, questionnaires were distributed to CML children aged <18 years at the time of diagnosis who were receiving imatinib for at least 3 months or to their parents in China. The height-for-age standard deviation score (HtSDS) and the difference of standard deviation integral (△HtSDS) were used to explore the change in height with imatinib therapy.Results:The data of 238 respondents were included; 138 (58.0% ) respondents were men. The median age at the first diagnosis of CML was 11.0 years (range, 1.4-17.9 years) , and 93 (39.0% ) respondents were at the prepuberty stage. At the time of completing the questionnaires, the median age was 15.0 years (range, 2.0-34.0 years) . The median duration of imatinib therapy was 28 months (range, 3-213 months) . Among all the respondents, the mean HtSDS when completing the questionnaires (-0.063±1.361) was significantly lower than that at the time of starting imatinib treatment (0.391±1.244) ( P<0.001) . Total 71.0% respondents showed growth impairment that was more common in those starting imatinib therapy at prepubertal age than in those starting at pubertal age. Multivariate analysis showed that younger at the start of imatinib therapy ( P<0.001) and longer duration of imatinib therapy ( P<0.001) were significantly associated with severe growth impairment on imatinib therapy. Conclusions:Imatinib induced growth impairment in children with CML-CP. Younger the age of initiation and longer the duration of imatinib therapy, more obvious the effect of imatinib on growth impairment.